Home>>Peptides>>IRBP (1-20), human TFA

IRBP (1-20), human TFA (Synonyms: 20mg/ml in Water)

Catalog No.GC61498

IRBP (1-20), human TFA contains a major epitope for the H-2b haplotype.

Products are for research use only. Not for human use. We do not sell to patients.

IRBP (1-20), human TFA Chemical Structure

Size Price Stock Qty
1 mg
$167.00
In stock
5 mg
$445.00
In stock
10 mg
$742.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

IRBP (1-20), human TFA contains a major epitope for the H-2b haplotype. IRBP (1-20), human TFA induces experimental autoimmune uveoretinitis (EAU) in H-2b mice[1][2].

IRBP (1-20), human TFA induces EAU[2].For determination of proliferative and cytokine responses, lymph node and spleen cells are collected 21 days after immunization and are stimulated in culture with the appropriate antigen. Cells of C57BL/6 mice and 129/J mice immunized with IRBP (1-20), human TFA proliferated in response to the peptide[2]. Animal Model: C57BL/6 (H-2b) mice, H-2b (C57BL/6, 129/J) mice[2]

[1]. Avichezer D, et al. Residues 1-20 of IRBP and whole IRBP elicit different uveitogenic and immunological responses in interferon gamma deficient mice. Exp Eye Res. 2000;71(2):111‐118. [2]. Avichezer D, Silver PB, Chan CC, Wiggert B, Caspi RR. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype. Invest Ophthalmol Vis Sci. 2000;41(1):127‐131.

Reviews

Review for IRBP (1-20), human TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for IRBP (1-20), human TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.